Investment Thesis
Medtronic demonstrates exceptional financial health with robust profitability margins (17.3% operating margin), strong free cash flow generation ($3.3B annually), and a solid balance sheet with conservative leverage (0.57x debt/equity). The company's strong liquidity position (2.54x current ratio) combined with healthy interest coverage (6.4x) indicates excellent capacity to service debt and invest in growth.
MDT Strengths
- Strong operational efficiency with 17.3% operating margin and 13.4% net margin
- Robust free cash flow of $3.3B with 12.6% FCF margin providing capital flexibility
- Conservative leverage at 0.57x debt/equity with excellent interest coverage of 6.4x
- Solid liquidity position with 2.54x current ratio and 1.87x quick ratio
- Substantial revenue base of $26.6B indicating scale and market presence
- Operating cash flow of $4.8B covering capex 3.4x over, demonstrating cash generation strength
MDT Risks
- Extreme revenue growth of 6463% YoY suggests data anomaly or major acquisition/accounting change requiring verification
- Concerning ROE of 7.3% and ROA of 3.9% indicate relatively low returns on deployed capital despite strong margins
- High long-term debt of $27.9B represents significant financial obligation requiring ongoing service capacity
- Declining net income (-0.6% YoY) despite massive revenue growth raises questions about underlying business momentum and cost structure
- Low cash position of $1.1B relative to $91.5B in assets suggests limited financial cushion for unexpected challenges
Key Metrics to Watch
- Organic revenue growth rate (excluding acquisition impact) to validate underlying business growth
- Trend in ROE and ROA to assess capital deployment efficiency improvements
- Net income growth trajectory to confirm profitability sustainability
- Free cash flow consistency and conversion rate from operating cash flow
- Debt reduction progress and leverage ratio trajectory
- Operating margin sustainability amid potential cost inflation
MDT Financial Metrics
MDT Profitability Ratios
MDT Balance Sheet & Liquidity
MDT 5-Year Financial Trend
5-Year Trend Summary: Medtronic plc's revenue has shown modest growth of 10% over the 5-year period. The most recent EPS of $2.82 reflects profitable operations.
MDT Growth Metrics (YoY)
MDT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $8.3B | $1.1B | $0.89 |
| Q2 2026 | $8.4B | $1.3B | $0.99 |
| Q1 2026 | $7.9B | $1.0B | $0.80 |
| Q3 2025 | $8.1B | $1.3B | $0.99 |
| Q2 2025 | $8.0B | $909.0M | $0.68 |
| Q1 2025 | $7.7B | $791.0M | $0.59 |
| Q3 2024 | $7.7B | $1.2B | $0.92 |
| Q2 2024 | $7.6B | $427.0M | $0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MDT Capital Allocation
MDT SEC Filings
Access official SEC EDGAR filings for Medtronic plc (CIK: 0001613103)